Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels

@article{Micale2009AnxiolyticEI,
  title={Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels},
  author={Vincenzo Micale and Luigia Cristino and Alessandra Tamburella and Stefania Rehnelt Jennifer Petrosino and Gian Marco Leggio and Filippo Drago and Vincenzo di Marzo},
  journal={Neuropsychopharmacology},
  year={2009},
  volume={34},
  pages={593-606}
}
The endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), and the transient receptor potential vanilloid type-1 (TRPV1) channel are new targets for the development of anxiolytic drugs. We studied the effect on anxiety-like behavior in the elevated plus maze of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT). In male C57BL/6J mice, acute intraperitoneal administration of AA-5-HT (0.1–2.5 mg/kg) increased both the time spent and the number of entries in the open… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 85 CITATIONS, ESTIMATED 43% COVERAGE

Effects of Endocannabinoid System Modulation on Cognitive and Emotional Behavior

  • Front. Behav. Neurosci.
  • 2011
VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 62 REFERENCES

Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors

  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2004
VIEW 20 EXCERPTS
HIGHLY INFLUENTIAL

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

L Van Gaal, X Pi-Sunyer, JP Després, C McCarthy, A Scheen
  • Diabetes Care 31(Suppl 2): S229–S240.
  • 2008
VIEW 1 EXCERPT
HIGHLY INFLUENTIAL

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

L Van Gaal, X Pi-Sunyer, JP Després, C McCarthy, A Scheen
  • Diabetes Care 31(Suppl 2): S229–S240.
  • 2008
VIEW 1 EXCERPT
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…